| Madison Roland, | |
|
526 Boll Weevil Cir, Enterprise, AL 36330-4012 | |
| (334) 596-0953 | |
| Not Available |
| Full Name | Madison Roland |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 526 Boll Weevil Cir, Enterprise, Alabama |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154746543 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | SZ6582 (Florida) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Madison Roland, 526 Boll Weevil Cir, Enterprise, AL 36330-4012 Ph: (334) 596-0953 | Madison Roland, 526 Boll Weevil Cir, Enterprise, AL 36330-4012 Ph: (334) 596-0953 |
News Archive
The U.S. Food and Drug Administration today approved Brisdelle (paroxetine) to treat moderate to severe hot flashes (vasomotor symptoms) associated with menopause. Brisdelle, which contains the selective serotonin reuptake inhibitor paroxetine mesylate, is currently the only non-hormonal treatment for hot flashes approved by the FDA.
ZONARE Medical Systems, Inc., a developer of premium ultrasound solutions, will showcase the z.one system focused on abdominal ultrasound imaging solutions for diverse patient populations here shown at the 97th Annual Meeting of the Radiology Society of North America, November 27 – December 2.
H. Lundbeck A/S (Lundbeck) and Merck, known outside the United States and Canada as MSD, today announced a commercialization agreement for SYCREST (asenapine) sublingual tablets (5 mg, 10 mg). Under the terms of the agreement, Lundbeck will pay an undisclosed fee as well as product supply payments in exchange for exclusive commercial rights to SYCREST in all markets outside the United States, China and Japan. Lundbeck expects to launch SYCREST in the European Union (EU), where it is already approved, at the beginning of 2011.
Array BioPharma Inc. has announced the presentation of preclinical data on a novel small molecule glucokinase activator (GKA), ARRY-403, a drug for the treatment of Type 2 diabetes.
In a rigorous new review of the antiarrhythmic drug dronedarone (Multaq), researchers at the Cedars-Sinai Heart Institute conclude that the controversial drug is only modestly effective and has no clear safety benefits.
› Verified 9 days ago
Mrs. Tonya D Ray, MS CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 611 Glover Ave, Enterprise, AL 36330 Phone: 334-477-6183 Fax: 334-894-9029 | |
Rebekah Traylor, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1032 Boll Weevil Cir Ste E-g, Enterprise, AL 36330 Phone: 334-475-2006 Fax: 334-475-2021 | |
Dialogue Therapy Services, Llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 611 Glover Ave, Enterprise, AL 36330 Phone: 334-477-6183 | |
Caitlyn Martin, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1032 Boll Weevil Cir Ste F-g, Enterprise, AL 36330 Phone: 334-475-2006 Fax: 334-475-2021 |